-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Inari Medical Analyst Ratings
Inari Medical Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/16/2022 | 27.46% | Canaccord Genuity | $92 → $94 | Maintains | Buy |
09/13/2022 | 17.97% | Truist Securities | → $87 | Initiates Coverage On | → Hold |
07/15/2022 | 26.1% | Morgan Stanley | $108 → $93 | Maintains | Overweight |
06/24/2022 | 35.59% | BTIG | $130 → $100 | Maintains | Buy |
06/21/2022 | 35.59% | Piper Sandler | → $100 | Initiates Coverage On | → Overweight |
03/14/2022 | 30.17% | Canaccord Genuity | $102 → $96 | Maintains | Buy |
02/24/2022 | 46.44% | Morgan Stanley | $119 → $108 | Maintains | Overweight |
02/24/2022 | 28.81% | SVB Leerink | $85 → $95 | Maintains | Outperform |
11/10/2021 | 62.71% | SVB Leerink | $110 → $120 | Maintains | Outperform |
08/11/2021 | 49.15% | SVB Leerink | $126 → $110 | Maintains | Outperform |
05/12/2021 | 78.98% | Canaccord Genuity | $129 → $132 | Maintains | Buy |
05/12/2021 | 74.92% | Morgan Stanley | $126 → $129 | Maintains | Overweight |
03/10/2021 | 69.49% | Wells Fargo | $112 → $125 | Maintains | Overweight |
03/10/2021 | 74.92% | Canaccord Genuity | $94 → $129 | Reiterates | → Buy |
03/10/2021 | 70.85% | Morgan Stanley | $85 → $126 | Maintains | Overweight |
03/10/2021 | 70.85% | SVB Leerink | $116 → $126 | Maintains | Outperform |
12/15/2020 | 7.12% | Wells Fargo | → $79 | Upgrades | Equal-Weight → Overweight |
11/18/2020 | 24.75% | BTIG | → $92 | Initiates Coverage On | → Buy |
11/13/2020 | 15.25% | Morgan Stanley | $76 → $85 | Maintains | Overweight |
11/13/2020 | 22.03% | SVB Leerink | $80 → $90 | Maintains | Outperform |
09/28/2020 | 8.47% | SVB Leerink | → $80 | Initiates Coverage On | → Outperform |
08/12/2020 | -10.51% | Morgan Stanley | $52 → $66 | Maintains | Equal-Weight |
06/22/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/19/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/16/2020 | -33.56% | Wells Fargo | → $49 | Initiates Coverage On | → Equal-Weight |
06/16/2020 | -29.49% | Morgan Stanley | → $52 | Initiates Coverage On | → Equal-Weight |
Inari Medical Questions & Answers
The latest price target for Inari Medical (NASDAQ: NARI) was reported by Canaccord Genuity on September 16, 2022. The analyst firm set a price target for $94.00 expecting NARI to rise to within 12 months (a possible 27.46% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for Inari Medical (NASDAQ: NARI) was provided by Canaccord Genuity, and Inari Medical maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inari Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inari Medical was filed on September 16, 2022 so you should expect the next rating to be made available sometime around September 16, 2023.
While ratings are subjective and will change, the latest Inari Medical (NARI) rating was a maintained with a price target of $92.00 to $94.00. The current price Inari Medical (NARI) is trading at is $73.75, which is out of the analyst's predicted range.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
09/16/2022 | 27.46% | Canaccord Genuity | $92 → $94 | Maintains | Buy |
09/13/2022 | 17.97% | Truist Securities | → $87 | Initiates Coverage On | → Hold |
07/15/2022 | 26.1% | Morgan Stanley | $108 → $93 | Maintains | Overweight |
06/24/2022 | 35.59% | BTIG | $130 → $100 | Maintains | Buy |
06/21/2022 | 35.59% | Piper Sandler | → $100 | Initiates Coverage On | → Overweight |
03/14/2022 | 30.17% | Canaccord Genuity | $102 → $96 | Maintains | Buy |
02/24/2022 | 46.44% | Morgan Stanley | $119 → $108 | Maintains | Overweight |
02/24/2022 | 28.81% | SVB Leerink | $85 → $95 | Maintains | Outperform |
11/10/2021 | 62.71% | SVB Leerink | $110 → $120 | Maintains | Outperform |
08/11/2021 | 49.15% | SVB Leerink | $126 → $110 | Maintains | Outperform |
05/12/2021 | 78.98% | Canaccord Genuity | $129 → $132 | Maintains | Buy |
05/12/2021 | 74.92% | Morgan Stanley | $126 → $129 | Maintains | Overweight |
03/10/2021 | 69.49% | Wells Fargo | $112 → $125 | Maintains | Overweight |
03/10/2021 | 74.92% | Canaccord Genuity | $94 → $129 | Reiterates | → Buy |
03/10/2021 | 70.85% | Morgan Stanley | $85 → $126 | Maintains | Overweight |
03/10/2021 | 70.85% | SVB Leerink | $116 → $126 | Maintains | Outperform |
12/15/2020 | 7.12% | Wells Fargo | → $79 | Upgrades | Equal-Weight → Overweight |
11/18/2020 | 24.75% | BTIG | → $92 | Initiates Coverage On | → Buy |
11/13/2020 | 15.25% | Morgan Stanley | $76 → $85 | Maintains | Overweight |
11/13/2020 | 22.03% | SVB Leerink | $80 → $90 | Maintains | Outperform |
09/28/2020 | 8.47% | SVB Leerink | → $80 | Initiates Coverage On | → Outperform |
08/12/2020 | -10.51% | Morgan Stanley | $52 → $66 | Maintains | Equal-Weight |
06/22/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/19/2020 | -18.64% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
06/16/2020 | -33.56% | Wells Fargo | → $49 | Initiates Coverage On | → Equal-Weight |
06/16/2020 | -29.49% | Morgan Stanley | → $52 | Initiates Coverage On | → Equal-Weight |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
2022 年 9 月 16 日 | 27.46% | Canaccord Genu | 92 美元 → 94 美元 | 维护 | 买 |
09/13/2022 | 17.97% | 信实证券 | → 87 美元 | 启动覆盖范围开启 | → 按住 |
07/15/2022 | 26.1% | 摩根士丹利 | 108 美元 → 93 美元 | 维护 | 超重 |
2022 年 6 月 24 日 | 35.59% | BTIG | 130 美元 → 100 美元 | 维护 | 买 |
2022 年 6 月 21 日 | 35.59% | 派珀·桑德勒 | → 100 美元 | 启动覆盖范围开启 | → 超重 |
03/14/2022 | 30.17% | Canaccord Genu | 102 美元 → 96 美元 | 维护 | 买 |
2022 年 2 月 24 日 | 46.44% | 摩根士丹利 | 119 美元 → 108 美元 | 维护 | 超重 |
2022 年 2 月 24 日 | 28.81% | SVB Leerink | 85 美元 → 95 美元 | 维护 | 跑赢大盘 |
11/10/2021 | 62.71% | SVB Leerink | 110 美元 → 120 美元 | 维护 | 跑赢大盘 |
08/11/2021 | 49.15% | SVB Leerink | 126 美元 → 110 美元 | 维护 | 跑赢大盘 |
2021 年 12 月 5 日 | 78.98% | Canaccord Genu | 129 美元 → 132 美元 | 维护 | 买 |
2021 年 12 月 5 日 | 74.92% | 摩根士丹利 | 126 美元 → 129 美元 | 维护 | 超重 |
03/10/2021 | 69.49% | 富国银行 | 112 美元 → 125 美元 | 维护 | 超重 |
03/10/2021 | 74.92% | Canaccord Genu | 94 美元 → 129 美元 | 重申 | → 购买 |
03/10/2021 | 70.85% | 摩根士丹利 | 85 美元 → 126 美元 | 维护 | 超重 |
03/10/2021 | 70.85% | SVB Leerink | 116 美元 → 126 美元 | 维护 | 跑赢大盘 |
2020 年 12 月 15 日 | 7.12% | 富国银行 | → 79 美元 | 升级 | 重量相等 → 超重 |
2020 年 11 月 18 日 | 24.75% | BTIG | → 92 美元 | 启动覆盖范围开启 | → 购买 |
11/13/2020 | 15.25% | 摩根士丹利 | 76 美元 → 85 美元 | 维护 | 超重 |
11/13/2020 | 22.03% | SVB Leerink | 80 美元 → 90 美元 | 维护 | 跑赢大盘 |
09/28/2020 | 8.47% | SVB Leerink | → 80 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
08/12/2020 | -10.51% | 摩根士丹利 | 52 美元 → 66 美元 | 维护 | 重量相等 |
2020 年 6 月 22 日 | -18.64% | Canaccord Genu | → 60 美元 | 启动覆盖范围开启 | → 购买 |
2020 年 6 月 19 日 | -18.64% | Canaccord Genu | → 60 美元 | 启动覆盖范围开启 | → 购买 |
06/16/2020 | -33.56% | 富国银行 | → 49 美元 | 启动覆盖范围开启 | → 重量相等 |
06/16/2020 | -29.49% | 摩根士丹利 | → 52 美元 | 启动覆盖范围开启 | → 重量相等 |
Inari Medical Questions & Answers
稻荷医疗问题与解答
The latest price target for Inari Medical (NASDAQ: NARI) was reported by Canaccord Genuity on September 16, 2022. The analyst firm set a price target for $94.00 expecting NARI to rise to within 12 months (a possible 27.46% upside). 9 analyst firms have reported ratings in the last year.
Canaccord Genuity于2022年9月16日公布了Inari Medical(纳斯达克股票代码:NARI)的最新目标股价。该分析公司将目标股价定为94.00美元,预计NARI将在12个月内升至12个月内(可能上涨27.46%)。去年有9家分析公司公布了评级。
The latest analyst rating for Inari Medical (NASDAQ: NARI) was provided by Canaccord Genuity, and Inari Medical maintained their buy rating.
Canaccord Genuity对Inari Medical(纳斯达克股票代码:NARI)的最新分析师评级由Canaccord Genuity提供,Inari Medical维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inari Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inari Medical was filed on September 16, 2022 so you should expect the next rating to be made available sometime around September 16, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Inari Medical的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Inari Medical的最新评级是在2022年9月16日公布的,因此您应该预计下一个评级将在2023年9月16日左右公布。
While ratings are subjective and will change, the latest Inari Medical (NARI) rating was a maintained with a price target of $92.00 to $94.00. The current price Inari Medical (NARI) is trading at is $73.75, which is out of the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Inari Medical(NARI)评级保持不变,目标股价为92.00美元至94.00美元。Inari Medical(NARI)目前的交易价格为73.75美元,超出了分析师的预期区间。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧